Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M Hyman

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2020
ForewordD M Hyman, M Ladanyi
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2021
Building bridges between drug development and cancer science: a tribute to José Baselga's legacyD M Hyman, J-C Soria, J Tabernero
JCO Precision Oncology|June 21, 2019
Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent GliomaA M Schram, P Jonsson, A Drilon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2019
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)R Condorelli, F Mosele, B Verret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2020
Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patientsD S Ross, B Liu, A M Schram, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Clinical and molecular characterization of patients with cancer of unknown primary in the modern eraA M Varghese, A Arora, M Capanu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2014
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancerJ L Meisel, D M Hyman, K Garg, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencingA M Schram, D Reales, J Galle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Characterization of on-target adverse events caused by TRK inhibitor therapyD Liu, J Flory, A Lin, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2020
ForewordD M Hyman, M Ladanyi
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2021
Building bridges between drug development and cancer science: a tribute to José Baselga's legacyD M Hyman, J-C Soria, J Tabernero
JCO Precision Oncology|June 21, 2019
Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent GliomaA M Schram, P Jonsson, A Drilon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2019
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)R Condorelli, F Mosele, B Verret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2020
Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patientsD S Ross, B Liu, A M Schram, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Clinical and molecular characterization of patients with cancer of unknown primary in the modern eraA M Varghese, A Arora, M Capanu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2014
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancerJ L Meisel, D M Hyman, K Garg, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencingA M Schram, D Reales, J Galle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Characterization of on-target adverse events caused by TRK inhibitor therapyD Liu, J Flory, A Lin, et al.
Pageof 2